Wealth Alliance Sells 870 Shares of DexCom, Inc. (NASDAQ:DXCM)

Wealth Alliance trimmed its stake in shares of DexCom, Inc. (NASDAQ:DXCMFree Report) by 16.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,550 shares of the medical device company’s stock after selling 870 shares during the quarter. Wealth Alliance’s holdings in DexCom were worth $425,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of DXCM. Mirae Asset Global Investments Co. Ltd. grew its position in DexCom by 31.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 270,999 shares of the medical device company’s stock worth $138,643,000 after acquiring an additional 65,516 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its position in DexCom by 3,596.7% during the 1st quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,109 shares of the medical device company’s stock worth $567,000 after acquiring an additional 1,079 shares during the last quarter. West Family Investments Inc. bought a new position in DexCom during the 1st quarter worth approximately $209,000. Ergoteles LLC grew its position in DexCom by 60.6% during the 1st quarter. Ergoteles LLC now owns 1,681 shares of the medical device company’s stock worth $860,000 after acquiring an additional 634 shares during the last quarter. Finally, Mackenzie Financial Corp grew its position in shares of DexCom by 26.4% in the 1st quarter. Mackenzie Financial Corp now owns 29,516 shares of the medical device company’s stock worth $15,100,000 after buying an additional 6,160 shares during the last quarter. 93.88% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. Piper Sandler lifted their price objective on DexCom from $135.00 to $150.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 19th. Wells Fargo & Company lifted their price objective on DexCom from $110.00 to $136.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 13th. JPMorgan Chase & Co. lowered their target price on DexCom from $160.00 to $100.00 and set an “overweight” rating for the company in a research note on Tuesday, October 17th. SVB Leerink started coverage on DexCom in a research note on Monday, October 16th. They issued an “outperform” rating and a $110.00 target price for the company. Finally, Morgan Stanley raised their target price on DexCom from $101.00 to $122.00 and gave the company an “equal weight” rating in a research note on Monday, December 4th. Three analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $134.64.

View Our Latest Stock Report on DXCM

Insider Buying and Selling

In related news, COO Jacob Steven Leach sold 3,978 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $123.63, for a total transaction of $491,800.14. Following the completion of the sale, the chief operating officer now directly owns 262,499 shares of the company’s stock, valued at approximately $32,452,751.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other DexCom news, Director Steven Robert Pacelli sold 411 shares of the firm’s stock in a transaction on Friday, November 24th. The stock was sold at an average price of $110.80, for a total transaction of $45,538.80. Following the transaction, the director now directly owns 124,775 shares in the company, valued at approximately $13,825,070. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Jacob Steven Leach sold 3,978 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $123.63, for a total value of $491,800.14. Following the transaction, the chief operating officer now owns 262,499 shares in the company, valued at $32,452,751.37. The disclosure for this sale can be found here. In the last three months, insiders sold 58,098 shares of company stock valued at $7,091,785. Insiders own 0.41% of the company’s stock.

DexCom Price Performance

NASDAQ:DXCM opened at $120.47 on Friday. The firm has a market capitalization of $46.55 billion, a price-to-earnings ratio of 91.96, a PEG ratio of 2.35 and a beta of 1.20. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $139.55. The business has a 50 day simple moving average of $123.34 and a 200-day simple moving average of $108.50. The company has a debt-to-equity ratio of 1.07, a current ratio of 2.80 and a quick ratio of 2.50.

DexCom (NASDAQ:DXCMGet Free Report) last posted its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.07. The business had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 27.88% and a net margin of 14.95%. The company’s revenue for the quarter was up 26.9% on a year-over-year basis. During the same period last year, the company earned $0.34 EPS. Equities analysts forecast that DexCom, Inc. will post 1.73 EPS for the current year.

DexCom Profile

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Read More

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCMFree Report).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.